首页> 外文期刊>JAMA: the Journal of the American Medical Association >Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
【24h】

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

机译:BRCA1或BRCA2突变携带者的降低风险的手术与癌症风险和死亡率的关联。

获取原文
获取原文并翻译 | 示例
       

摘要

CONTEXT: Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks of breast and ovarian cancer. OBJECTIVE: To estimate risk and mortality reduction stratified by mutation and prior cancer status. DESIGN, SETTING, AND PARTICIPANTS: Prospective, multicenter cohort study of 2482 women with BRCA1 or BRCA2 mutations ascertained between 1974 and 2008. The study was conducted at 22 clinical and research genetics centers in Europe and North America to assess the relationship of risk-reducing mastectomy or salpingo-oophorectomy with cancer outcomes. The women were followed up until the end of 2009. MAIN OUTCOMES MEASURES: Breast and ovarian cancer risk, cancer-specific mortality, and overall mortality. RESULTS: No breast cancers were diagnosed in the 247 women with risk-reducing mastectomy compared with 98 women of 1372 diagnosed with breast cancer who did not have risk-reducing mastectomy. Compared with women who did not undergo risk-reducing salpingo-oophorectomy, women who underwent salpingo-oophorectomy had a lower risk of ovarian cancer, including those with prior breast cancer (6% vs 1%, respectively; hazard ratio [HR], 0.14; 95% confidence interval [CI], 0.04-0.59) and those without prior breast cancer (6% vs 2%; HR, 0.28 [95% CI, 0.12-0.69]), and a lower risk of first diagnosis of breast cancer in BRCA1 mutation carriers (20% vs 14%; HR, 0.63 [95% CI, 0.41-0.96]) and BRCA2 mutation carriers (23% vs 7%; HR, 0.36 [95% CI, 0.16-0.82]). Compared with women who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy was associated with lower all-cause mortality (10% vs 3%; HR, 0.40 [95% CI, 0.26-0.61]), breast cancer-specific mortality (6% vs 2%; HR, 0.44 [95% CI, 0.26-0.76]), and ovarian cancer-specific mortality (3% vs 0.4%; HR, 0.21 [95% CI, 0.06-0.80]). CONCLUSIONS: Among a cohort of women with BRCA1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower risk of breast cancer; risk-reducing salpingo-oophorectomy was associated with a lower risk of ovarian cancer, first diagnosis of breast cancer, all-cause mortality, breast cancer-specific mortality, and ovarian cancer-specific mortality.
机译:背景:乳房切除术和输卵管卵巢切除术被BRCA1或BRCA2突变的携带者广泛使用,以降低其患乳腺癌和卵巢癌的风险。目的:评估按突变和既往癌症状况分层的风险和死亡率降低。设计,地点和参与者:1974年至2008年间对2482例具有BRCA1或BRCA2突变的女性进行了前瞻性,多中心队列研究。该研究在欧洲和北美的22个临床和研究遗传学中心进行,以评估降低风险的关系乳房切除术或输卵管卵巢切除术具有癌症结局。对妇女进行了随访,直到2009年底。主要指标:乳腺癌和卵巢癌的风险,特定癌症的死亡率以及总死亡率。结果:247例降低风险的乳房切除术未诊断出乳腺癌,而1372例经诊断未降低风险的乳房切除术的女性中有98例没有被诊断为乳腺癌。与未进行降低风险的输卵管卵巢切除术的女性相比,接受输卵管卵巢切除术的女性卵巢癌的风险更低,包括那些患有乳腺癌的女性(分别为6%和1%;危险比[HR]为0.14) ; 95%的置信区间[CI]为0.04-0.59)和无乳腺癌的患者(分别为6%和2%; HR为0.28 [95%CI为0.12-0.69]),首次诊断乳腺癌的风险较低BRCA1突变携带者(20%vs 14%; HR,0.63 [95%CI,0.41-0.96])和BRCA2突变携带者(23%vs 7%; HR,0.36 [95%CI,0.16-0.82])。与未进行降低风险的输卵管卵巢切除术的女性相比,接受输卵管卵巢切除术的女性全因死亡率较低(10%vs 3%; HR,0.40 [95%CI,0.26-0.61]),乳腺癌-特异性死亡率(6%vs 2%; HR,0.44 [95%CI,0.26-0.76])和卵巢癌特异性死亡率(3%vs 0.4%; HR,0.21 [95%CI,0.06-0.80])。结论:在一群具有BRCA1和BRCA2突变的女性中,使用降低风险的乳房切除术可降低乳腺癌的发生风险。降低风险的输卵管卵巢切除术与较低的卵巢癌风险,乳腺癌的首次诊断,全因死亡率,特定于乳腺癌的死亡率和特定于卵巢癌的死亡率相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号